Select Language
CEACAM-5
CEACAM-5 Overview
| English Name | Carcinoembryonic antigen related cell adhesion molecule 5 | Approved Drugs | 0 |
| Drugs in Clinical Trials | 14 | Target Synonym | CEA Cell Adhesion Molecule 5，CEACAM5，Meconium antigen 100，CEA，Carcinoembryonic Antigen Related Cell Adhesion Molecule 5，Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5，Carcinoembryonic Antigen，CD66e Antigen，CD66e |
| Highest Development Stage | Phase 3 Clinical | ||
| English Name | Carcinoembryonic antigen related cell adhesion molecule 5 |
| Target Synonym | CEA Cell Adhesion Molecule 5，CEACAM5，Meconium antigen 100，CEA，Carcinoembryonic Antigen Related Cell Adhesion Molecule 5，Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5，Carcinoembryonic Antigen，CD66e Antigen，CD66e |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 14 |
| Highest Development Stage | Phase 3 Clinical |
CEACAM-5 Product List
- Product Category
Protein (18)Cell (1)Cell Grade Beads (1)Beads (1)
- Product Status
Launched (21)
- Species
Human (15)Mouse (2)Cynomolgus (3)Rhesus macaque (1)
- Tag
His Tag (8)His Tag & Avi Tag (4)Fc Tag (3)Fc Tag & Avi Tag (1)Llama IgG Fc Tag (2)- (3)
- Conjugate
Unconjugated (11)Biotin-labeled (5)FITC Labeled (2)- (3)
Add to Cart
Total: 21
- 1
- 2
- 3
CEACAM-5 Background
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is also Carcinoembryonic antigen (CEA), Meconium antigen 100, CD antigen CD66e, CEACAM5 belongs to the immunoglobulin superfamily and CEA family. CEACAM5 contains seven Ig-like (immunoglobulin-like) domains. CEACAM5 is homodimer protein which binding of E.coli Dr adhesins leads to dissociation of the homodimer. CEACAM5 is cell surface glycoprotein that plays a role in cell adhesion and in intracellular signaling. CEACAM5 is receptor for E.coli Dr adhesins.
CEACAM-5 Synonyms
CEACAM-5,CD66e,CEA,Meconium antigen 100
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Tusamitamab Ravtansine | SAR-408701; IBI-126 | Phase 3 Clinical | Immunogen Inc | Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Metastatic breast cancer; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
| SGM-101 | SGM-101 | Phase 3 Clinical | Surgimab Sas | Intestinal Neoplasms; Gastrointestinal Diseases; Rectal Neoplasms; Brain Diseases; Colonic Neoplasms; Pancreatic Neoplasms; Brain Neoplasms; Colorectal Neoplasms; Colonic Diseases; Brain metastases; Intestinal Diseases; Gastrointestinal Neoplasms | Details |
| Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute) | CVAC-301; CV-301 | Phase 2 Clinical | Therion Biologics | Intestinal Neoplasms; Solid tumours; Cystadenocarcinoma; Ovarian Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Melanoma; Neoplasm Metastasis; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| NEO-201 | NEO-201 | Phase 2 Clinical | Precision Biologics Inc, National Cancer Institute | Squamous Cell Carcinoma of Head and Neck; Uterine Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Anti-CEA CAR T cell therapy (Shanghai GeneChem) | Phase 2 Clinical | Shanghai Genechem Co Ltd | Liver Neoplasms; Colorectal Neoplasms | Details | |
| LM-24C5 | LM-24C5 | Phase 2 Clinical | LaNova Medicines Ltd | Solid tumours; Neoplasms | Details |
| M-9140 | M-9140; M9140 | Phase 2 Clinical | Merck KGaA, Darmstadt, Germany | Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
| MFE-23-CD3z T cell therapy (Cancer Research Technology) | Phase 1 Clinical | Cancer Research Technology | Neoplasms | Details | |
| 125-Iodine-labeled MFE-23 | Phase 1 Clinical | Cancer Research UK | Neoplasms | Details | |
| anti-CEA CAR-T cell therapy (Sorrento/TNK therapeutics/Roger Williams Medical Center) | Phase 1 Clinical | Beth Israel Deaconess Medical Center | Solid tumours; Liver Neoplasms; Pancreatic Neoplasms; Neoplasms; Neoplasm Metastasis; Adenocarcinoma | Details | |
| SGN-CEACAM5C | PF-08046050; SAR445953; SGN-CEACAM5C; SAR-445953 | Phase 1 Clinical | Seagen Inc, Sanofi | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
| EBC-129 | EBC-129; EBC129 | Phase 1 Clinical | Experimental Drug Development Centre | Solid tumours | Details |
| BGB-B167 | BGB-B167 | Phase 1 Clinical | BeOne Medicines Ltd | Solid tumours | Details |
| GB-5012 | GB-5012 | Clinical | Shanghai Genbase Biotechnology Co Ltd | Colonic Neoplasms | Details |
- Overview
- Product List
- Clinical Drug Information
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland